Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Cardiol ; 194: 7-12, 2015 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-26005802

RESUMEN

BACKGROUND: Patients with Marfan syndrome (MFS) have a highly variable occurrence of aortic complications. Aortic tortuosity is often present in MFS and may help to identify patients at risk for aortic complications. METHODS: 3D-visualization of the total aorta by MR imaging was performed in 211 adult MFS patients (28% with prior aortic root replacement) and 20 controls. A method to assess aortic tortuosity (aortic tortuosity index: ATI) was developed and reproducibility was tested. The relation between ATI and age, and body size and aortic dimensions at baseline was investigated. Relations between ATI at baseline and the occurrence of a clinical endpoint (aortic dissection, and/or aortic surgery) and aortic dilatation rate during 3 years of follow-up were investigated. RESULTS: ATI intra- and interobserver agreements were excellent (ICC: 0.968 and 0.955, respectively). Mean ATI was higher in 28 age-matched MFS patients than in the controls (1.92 ± 0.2 vs. 1.82 ± 0.1, p=0.048). In the total MFS cohort, mean ATI was 1.87 ± 0.20, and correlated with age (r=0.281, p<0.001), aortic root diameter (r=0.223, p=0.006), and aortic volume expansion rate (r=0.177, p=0.026). After 49.3 ± 8.8 months follow-up, 33 patients met the combined clinical endpoint (7 dissections) with a significantly higher ATI at baseline than patients without endpoint (1.98 ± 0.2 vs. 1.86 ± 0.2, p=0.002). Patients with an ATI>1.95 had a 12.8 times higher probability of meeting the combined endpoint (log rank-test, p<0.001) and a 12.1 times higher probability of developing an aortic dissection (log rank-test, p=0.003) compared to patients with an ATI<1.95. CONCLUSIONS: Increased ATI is associated with a more severe aortic phenotype in MFS patients.


Asunto(s)
Enfermedades de la Aorta/patología , Síndrome de Marfan/patología , Adulto , Disección Aórtica/patología , Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Bloqueadores del Receptor Tipo 1 de Angiotensina II/efectos adversos , Aorta/efectos de los fármacos , Aorta/patología , Enfermedades de la Aorta/tratamiento farmacológico , Dilatación Patológica/tratamiento farmacológico , Dilatación Patológica/patología , Femenino , Fibrilinas , Estudios de Seguimiento , Humanos , Losartán/administración & dosificación , Losartán/efectos adversos , Imagen por Resonancia Magnética , Masculino , Síndrome de Marfan/tratamiento farmacológico , Síndrome de Marfan/genética , Proteínas de Microfilamentos/metabolismo , Persona de Mediana Edad , Mutación , Fenotipo , Reproducibilidad de los Resultados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA